Wang Kai, Gao Fengqiang, Dong Siyi, Ding Jialu, Dong Libin, Shao Chuxiao, Wang Zhoucheng, Qiu Xun, Wei Xuyong, Wang Zhengxin, Yang Jiayin, Xia Qiang, Zheng Shusen, Xu Xiao
Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):854-867. doi: 10.21037/hbsn-22-304. Epub 2023 Feb 28.
Salvage liver transplantation (SLT) has been reported to be an efficient treatment option for patients with recurrent hepatocellular carcinoma (HCC) after liver resection (LR). However, for recipients who underwent liver transplantation (LT) due to recurrent HCC after LR in China, the selection criteria are not well established.
In this study, data from the China Liver Transplant Registry (CLTR) of 4,244 LT performed from January 2015 to December 2019 were examined, including 3,498 primary liver transplantation (PLT) and 746 SLT recipients. Propensity score matching (PSM) analysis was used to minimize between-group imbalances. The overall survival (OS) and disease-free survival (DFS) between PLT and SLT in recipients fulfilling the Milan or Hangzhou criteria were compared based on the multivariate analysis, nomograms were plotted to further classify the SLT group into low- and high-risk groups.
In this study, the 1-, 3- and 5-year OS and DFS of SLT recipients fulfilling Milan criteria (OS, P=0.01; DFS, P<0.001) or Hangzhou criteria (OS, P=0.03; DFS, P=0.003) were significantly reduced when compared to that of PLT group after PSM analysis. Independent risk factors, including preoperative transarterial chemoembolization (TACE), alpha fetoprotein (AFP) level, tumor maximum size and tumor total diameter were selected to draw a prognostic nomogram. The low-risk SLT recipients (1-year, 95.34%; 3-year, 84.26%; 5-year, 77.20%) showed a comparable OS with PLT recipients fulfilling Hangzhou criteria (P=0.107).
An optimal nomogram model for prognosis stratification and clinical decision guidance of SLT was established. The low-risk SLT recipients based on the nomograms showed comparable survival with those fulfilling Hangzhou criteria in PLT group.
据报道,挽救性肝移植(SLT)是肝切除术后复发性肝细胞癌(HCC)患者的一种有效治疗选择。然而,在中国,对于因肝切除术后复发性HCC而接受肝移植(LT)的受者,选择标准尚未明确确立。
在本研究中,对中国肝移植登记处(CLTR)2015年1月至2019年12月进行的4244例LT的数据进行了检查,包括3498例初次肝移植(PLT)和746例SLT受者。采用倾向评分匹配(PSM)分析以尽量减少组间不均衡。基于多变量分析,比较了符合米兰或杭州标准的受者中PLT和SLT之间的总生存期(OS)和无病生存期(DFS),绘制列线图以进一步将SLT组分为低风险和高风险组。
在本研究中,经PSM分析后,符合米兰标准(OS,P = 0.01;DFS,P < 0.001)或杭州标准(OS,P = 0.03;DFS,P = 0.003)的SLT受者的1年、3年和5年OS及DFS与PLT组相比显著降低。选择包括术前经动脉化疗栓塞(TACE)、甲胎蛋白(AFP)水平、肿瘤最大径和肿瘤总直径等独立危险因素来绘制预后列线图。低风险SLT受者(1年,95.34%;3年,84.26%;5年,77.20%)的OS与符合杭州标准的PLT受者相当(P = 0.107)。
建立了用于SLT预后分层和临床决策指导的最佳列线图模型。基于列线图的低风险SLT受者与PLT组中符合杭州标准的受者生存率相当。